MannKind Corporation in Transition
A drug on the market for two weeks makes for a boring earnings call.
Meet MannKind Corporation's New Boss (No, the Other One)
Sanofi's new CEO Olivier Brandicourt will have an impact on the success of MannKind's Afrezza.
3 Critical Questions MannKind Shareholders Need to Contemplate in 2015
With potentially game-changing diabetes therapy Afrezza now launched, shareholders can turn their attention to these three important questions.